These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 1705232)
1. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions. al-Saffar N; Hasleton PS Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232 [TBL] [Abstract][Full Text] [Related]
2. Reactive lesions of the pleura. Immunohistochemical characterization. Brockmann M; Brockmann I; Fischer M; Müller KM Pathol Res Pract; 1990 Apr; 186(2):238-46. PubMed ID: 1692994 [TBL] [Abstract][Full Text] [Related]
3. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin. Duggan MA; Masters CB; Alexander F Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical and histochemical markers of primary lung cancer, lung metastases, and pleural mesotheliomas. Popper H; Wirnsberger G; Hoefler H; Denk H Cancer Detect Prev; 1987; 10(3-4):167-74. PubMed ID: 2436780 [TBL] [Abstract][Full Text] [Related]
6. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877 [TBL] [Abstract][Full Text] [Related]
7. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions. Friedman MT; Gentile P; Tarectecan A; Fuchs A Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Roberts F; Harper CM; Downie I; Burnett RA Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073 [TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas--a clinicomorphological study of 158 cases. Vortmeyer AO; Preuss J; Padberg BC; Kastendieck H; Schröder S Anticancer Res; 1991; 11(2):889-94. PubMed ID: 1712181 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Wirth PR; Legier J; Wright GL Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Holden J; Churg A Am J Surg Pathol; 1984 Apr; 8(4):277-9. PubMed ID: 6201076 [TBL] [Abstract][Full Text] [Related]
12. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Corson JM; Pinkus GS Am J Pathol; 1982 Jul; 108(1):80-8. PubMed ID: 6178295 [TBL] [Abstract][Full Text] [Related]
13. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas. Tot T Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209 [TBL] [Abstract][Full Text] [Related]
14. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients. Kayser K; Böhm G; Blum S; Beyer M; Zink S; André S; Gabius HJ J Pathol; 2001 Feb; 193(2):175-80. PubMed ID: 11180163 [TBL] [Abstract][Full Text] [Related]
15. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265 [TBL] [Abstract][Full Text] [Related]
16. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen. Sheibani K; Battifora H; Burke JS Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942 [TBL] [Abstract][Full Text] [Related]
17. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Szpak CA; Johnston WW; Roggli V; Kolbeck J; Lottich SC; Vollmer R; Thor A; Schlom J Am J Pathol; 1986 Feb; 122(2):252-60. PubMed ID: 2418688 [TBL] [Abstract][Full Text] [Related]
18. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects]. Chenard-Neu MP; Bellocq JP; Maier A; Batzenschlager A Ann Pathol; 1990; 10(1):20-7. PubMed ID: 2328062 [TBL] [Abstract][Full Text] [Related]
19. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation. Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489 [TBL] [Abstract][Full Text] [Related]
20. Detection of tissue CEA-like substance as an aid in the differential diagnosis of malignant mesothelioma. Whitaker D; Sterrett GF; Shilkin KB Pathology; 1982 Jul; 14(3):255-8. PubMed ID: 6290965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]